IP Library Granted Patent US 8,420,396
Granted Patent B2
US 8,420,396 · App. 11/622,156 · Granted Apr 16, 2013

Conjugates and processes for their preparation and their use for transporting molecules across biological membranes

Inventors: Eugene Uhlmann (Glashuetten, DE); Beate Greiner (Leiderbach, DE); Eberhard Unger (Jena-Cospeda, DE); Gislinde Gothe (Jena-Cospeda, DE); Marc Schwerdel (Jena, DE)
Assignee: Sanofi-Aventis Deutschland GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,420,396
App. No.
11/622,156
Granted
Apr 16, 2013
Kind
B2
Abstract

The present invention provides conjugates, processes for their preparation, and the use of these conjugates for transporting low-molecular-weight compounds and macromolecules across biological membranes, in particular for transporting molecules into cells. The present invention also provides pharmaceutical compositions, diagnostic aids, and test kits in which these conjugates are present or used.

Claims (9)

1. A method for transporting an oligonucleotide across a membrane which comprises incubating a conjugate with the membrane, wherein the conjugate comprises the oligonucleotide attached to an aryl radical and has the following structure: 5′-F3-amino linker-phosphorothioate modified oligonucleotide with 12 or 15 nucleotides, wherein F3 is:

2. The method of claim 1 , wherein the oligonucleotide has a length of 8 to 80 nucleotides.

3. A method for transporting an oligonucleotide into a cell which comprises incubating a conjugate with the cell, wherein the conjugate comprises an oligonucleotide attached to an aryl radical and has the following structure: 5″-F3-amino linker-phosphorothioate modified oligonucleotide with 12 or 15 nucleotides, wherein F3 is:

and the conjugate is transported into the cell without the aryl radical being cleaved off.

4. The method as claimed in claim 3 , wherein the cell is a eukaryotic or a prokaryotic cell.

5. The method as claimed in claim 3 , wherein the cell is a bacterial cell, yeast cell or a mammalian cell.

6. The method as clamed in claim 3 , wherein the cell is a human.

7. The process as claimed in claim 3 , wherein the cell is a tumor cell.

8. The method of claim 3 , wherein the oligonucleotide has a length of 8 to 80 nucleotides.

Assignments (2)
CHANGE OF NAME Recorded Dec 19, 2012
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 029496/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2012
From: UHLMANN, EUGEN; GREINER, BEATE; UNGER, EBERHARD; GOTHE, GISLINDE; SCHWERDEL, MARC
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 029461/0426 →
Priority Claims (1)
DE 199 35 302 · Jul 28, 1999 · national
Continuity (2)
Continuation 09627787 · Jul 27, 2000
Related Publication 20080071069A1 · Mar 20, 2008